Integral Molecular
Integral Molecular is a research-driven biotechnology company with over 20 years of experience specializing in membrane proteins, antibodies, and virology. They develop innovative technologies and therapeutic antibodies targeting challenging membrane protein targets such as GPCRs, ion channels, transporters, and viral envelopes. Their mission is to advance therapeutic discovery against difficult protein targets through proprietary platforms like Lipoparticles, MPS Antibody Discovery, and Epitope Mapping, supporting over 600 customers worldwide and collaborating with top biotech and pharmaceutical companies.
Industries
Nr. of Employees
small (1-50)
Integral Molecular
One uCity Square 25 N. 38th St., Suite 800 Philadelphia, PA, 19104
Patents
Glucose transporter 4 antibodies, methods of making the same, and uses thereof
US-11834497-B2
View Details
Glucose transporter 4 antibodies, methods of making the same, and uses thereof
US-11834497-B2
View DetailsProducts
Virus-like particle reagents presenting membrane proteins
Noninfectious nanoscale particles that present conformationally intact membrane proteins at elevated surface concentration for immunization, display-based screening, ELISA, biosensor, and binding assays; available as custom batches, catalog items, or sample kits.
Proteome-scale cell-based specificity library (7,000+ proteins)
Unfixed cell expression library service representing thousands of human membrane and secreted proteins for off-target specificity testing, including expression QC, quantitative FACS readouts, hit validation, and regulatory-ready deliverables.
Replication-incompetent reporter virus particle kits
Validated reporter virus particle reagents bearing defined viral envelope proteins and optical reporters for infectivity and neutralization assays, provided with assay recommendations and permissive cell lines where applicable.
Virus-like particle reagents presenting membrane proteins
Noninfectious nanoscale particles that present conformationally intact membrane proteins at elevated surface concentration for immunization, display-based screening, ELISA, biosensor, and binding assays; available as custom batches, catalog items, or sample kits.
Proteome-scale cell-based specificity library (7,000+ proteins)
Unfixed cell expression library service representing thousands of human membrane and secreted proteins for off-target specificity testing, including expression QC, quantitative FACS readouts, hit validation, and regulatory-ready deliverables.
Replication-incompetent reporter virus particle kits
Validated reporter virus particle reagents bearing defined viral envelope proteins and optical reporters for infectivity and neutralization assays, provided with assay recommendations and permissive cell lines where applicable.
Services
Unfixed cell-based screening representing thousands of human membrane proteins, with optional parallel screening of secreted proteins, quantitative flow-cytometry readouts, built-in hit validation, and IND-oriented reporting workflows.
Statistical analysis of proteome-screen results, cellular localization context, relative binding strength assessment, and follow-up dose-response validation experiments to support lead selection and safety assessment.
Custom single-residue mutagenesis libraries expressed in human cells, high-throughput binding screens on live cells, control validations, and a final report delivering amino-acid-resolution epitope maps and publication-quality figures.
Library-based single-residue scanning across antibody CDRs with binding and expression readouts to define permissible substitutions and support antibody engineering and patent drafting; delivers full datasets and optional draft claim language.
Design and expression of arrays of single-amino-acid variant constructs in human cells, delivery of expressed supernatants, QC reports, and optional plasmid/glycerol stock provision for downstream assays.
Custom and prevalidated noninfectious particle reagents presenting specified membrane proteins at high density for immunization, screening, and biophysical assays; available with labeling and multiple QC metrics per batch.
Unfixed cell-based screening representing thousands of human membrane proteins, with optional parallel screening of secreted proteins, quantitative flow-cytometry readouts, built-in hit validation, and IND-oriented reporting workflows.
Statistical analysis of proteome-screen results, cellular localization context, relative binding strength assessment, and follow-up dose-response validation experiments to support lead selection and safety assessment.
Custom single-residue mutagenesis libraries expressed in human cells, high-throughput binding screens on live cells, control validations, and a final report delivering amino-acid-resolution epitope maps and publication-quality figures.
Library-based single-residue scanning across antibody CDRs with binding and expression readouts to define permissible substitutions and support antibody engineering and patent drafting; delivers full datasets and optional draft claim language.
Design and expression of arrays of single-amino-acid variant constructs in human cells, delivery of expressed supernatants, QC reports, and optional plasmid/glycerol stock provision for downstream assays.
Custom and prevalidated noninfectious particle reagents presenting specified membrane proteins at high density for immunization, screening, and biophysical assays; available with labeling and multiple QC metrics per batch.
Expertise Areas
- Proteome-scale specificity profiling for antibody and cell therapies
- High-resolution epitope mapping using single-residue mutagenesis
- Paratope mapping and CDR-scanning for antibody engineering and IP support
- Production and QC of membrane-protein-presenting virus-like particles
Key Technologies
- Shotgun mutagenesis (single-residue/alanine-scan) libraries
- Single–amino-acid CDR-scanning libraries
- High-throughput flow cytometry on live, unfixed cells
- Proteome-scale cell-based protein arrays
News & Updates
American Society for Virology
July 14th-17th, 2025, Montreal, QC
Immuno Oncology Summit
Aug 11th-13th, 2025, Philadelphia, PA
NIH Research Festival
Sep 11th-12th, 2025, Bethesda, MD
World Vaccine Congress – Europe
Oct 14th-16th, 2025, Amsterdam, NE
Integral Molecular’s platform for drug development qualification has been accepted by the FDA, advancing its use as a drug development tool.
American Society for Virology
July 14th-17th, 2025, Montreal, QC
Immuno Oncology Summit
Aug 11th-13th, 2025, Philadelphia, PA
NIH Research Festival
Sep 11th-12th, 2025, Bethesda, MD
World Vaccine Congress – Europe
Oct 14th-16th, 2025, Amsterdam, NE
Integral Molecular’s platform for drug development qualification has been accepted by the FDA, advancing its use as a drug development tool.